Simultaneous modulation of multidrug resistance and antiapoptotic cellular defense by MDR1 and BCL-2 targeted antisense oligonucleotides enhances the anticancer efficacy of doxorubicin

Pharmaceutical Research

Volumn 20, Issue 3, 2003, Pages 351-359

  Pakunlu, Refika I ^a   Cook, Thomas J ^a   Minko, Tamara ^a,b,c  

^a RUTGERS UNIVERSITY   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^c New Jersey Center for Biomaterials   (United States)

Author keywords

Antisense oligonucleotides; Apoptosis; Liposomes; Multidrug resistance; Ovarian and breast cancer

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CASPASE; DOXORUBICIN; GLYCOPROTEIN P; LIPOSOME; MESSENGER RNA; PROTEIN BCL 2;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CELL ASSAY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; ENZYME ACTIVATION; ENZYME ASSAY; GENETIC PARAMETERS; HUMAN; HUMAN CELL; INCUBATION TIME; MULTIDRUG RESISTANCE; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN SYNTHESIS;

ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOTIC PROTEASE-ACTIVATING FACTOR 1; BLOTTING, WESTERN; CASPASE 3; CASPASE 9; CASPASES; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LIPOSOMES; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; P-GLYCOPROTEIN; PROTEIN BIOSYNTHESIS; PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0037336279     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1022687617318     Document Type: Article

References (20)

1. T. Minko, P. Kopeckova, and J. Kopecek. Chronic exposure to HPMA copolymer bound adriamycin does not induce multidrug resistance in a human ovarian carcinoma cell line. J. Control. Release 59:133-148 (1999).
2. T. Minko, S. S. Dharap, R. I. Pakunlu, and J. L. Colaizzi. Advanced drug delivery systems in cancer chemotherapy. Dis. Management Clin. Outcomes 3:48-54 (2001).
3. M. M. Gottesman, T. Fojo, and S. E. Bates. Multidrug resistance in cancer: role of ATP-dependent transporters. Nature Rev. Cancer 2:48-58 (2002).
4. J. Kvackajova-Kisucka, M. Barancik, and A. Breier. Drug transporters and their role in multidrug resistance of neoplastic cells. Gen. Physiol. Biophys. 20:215-237 (2001).
5. T. Minko, P. Kopeckova, and J. Kopecek. Comparison of the anticancer effect of free and HPMA copolymer-bound adriamycin in human ovarian carcinoma cells. Pharm. Res. 16:986-996 (1999).
6. T. Minko, P. Kopeckova, and J. Kopecek. Efficacy of the chemotherapeutic action of HPMA copolymer-bound doxorubicin in a solid tumor model of ovarian carcinoma. Int. J. Cancer 86:108-117 (2000).
7. T. Minko, P. Kopeckova, and J. Kopecek. Preliminary evaluation of caspase-dependent apoptosis signaling pathways of free and HPMA copolymer-bound doxorubicin in human ovarian carcinoma cells. J. Control. Release 71:227-237 (2001).
8. S. K. Alahari, R. DeLong, M. H. Fisher, N. M. Dean, P. Viliet, and R. L. Juliano. Novel chemically modified oligonucleotides provide potent inhibition of P-glycoprotein expression. J. Pharmacol. Exp. Ther. 286:419-428 (1998).
9. M. V Corrias and G. P. Tonini. An oligomer complementary to the 5′ end region of MDR1 gene decreases resistance to doxorubicin of human adenocarcinoma-resistant cells. Anticancer Res. 12:1431-1438 (1992).
10. E. V. Kostenko, P. P. Laktionov, V. V. Vlassov, and M. A. Zenkova. Downregulation of PGY1/MDR1 mRNA level in human KB cells by antisense oligonucleotide conjugates. RNA accessibility in vitro and intracellular antisense activity. Biochim. Biophys. Acta 1576:143-147 (2002).
11. S. Motomura, T. Motoji, M. Takanashi, Y. H. Wang, H. Shiozaki, I. Sugawara, E. Aikawa, A. Tomida, T. Tsuruo, N. Kanda, and H. Mizoguchi. Inhibition of P-glycoprotein and recovery of drug sensitivity of human acute leukemic blast cells by multidrug resistance gene (mdr1) antisense oligonucleotides. Blood 91:3163-3171 (1998).
12. A. V. Kabanov and V. Y. Alakhov. Pluronic block copolymers in drug delivery: from micellar nanocontainers to biological response modifiers. Crit. Rev. Ther. Drug Carrier Syst. 19:1-72 (2002).
13. A. Gross, J. M. McDonnell, and S. Korsmeyer. BCL-2 family members and the mitochondria in apoptosis. Genes Dev. 13:1899-1911 (1999).
14. J. Reed. Dysregulation of apoptosis in cancer. J. Clin. Oncol. 17:2941-2953 (1999).
15. V. Poulaki, N. Mitsiades, M. E. Romero, and M. Tsokos. Fasmediated apoptosis in neuroblastoma requires mitochondrial activation and is inhibited by FLICE inhibitor protein and bcl-2. Cancer Res. 61:4864-4872 (2001).
16. D. E. L. de Mendes, N. Hudon, N. McIntosh, and L. D. Mayer. Molecular and pharmacokinetics properties associated with the therapeutics of Bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin. Clin. Cancer Res. 6:2891-2902 (2000).
17. M. Konopleva, A. M. Tari, Z. Estrov, D. Harris, Z. Xie, S. Zhao, G. Lopez-Berestein, and M. Andreeff. Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other antiapoptotic proteins. Blood 15:3929-3938 (2000).
18. T. Minko, A. Stefanov, and V. Pozharov. Lung hypoxia: Antioxidant and antiapoptotic effects of liposomal alpha tocopherol. J. Appl. Physiol. 93:1550-1560 (2002).
19. T. Minko, P. Kopeckova, V. Pozharov, and J. Kopecek. HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line. J. Control. Release 54:223-233 (1998).
20. T. Minko, P. Paranjpe, B. Qiu, A. Lalloo, R. Won, S. Stein, and P. J. Sinko. Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethylene glycol) conjugates in sensitive and multidrug resistant human ovarian carcinoma cells. Cancer Chemother. Pharm. 50:143-150 (2002).